Esterase activity in excised and reconstructed human skin-Biotransformation of prednicarbate and the model dye fluorescein diacetate

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 84, Issue 2, 2013, Pages 374-385

  Bätz, Franzisca Marie ^a   Klipper, Wiebke ^a   Korting, Hans Christian ^b   Henkler, Frank ^c   Landsiedel, Robert ^d   Luch, Andreas ^c   Von Fritschen, Uwe ^e   Weindl, Günther ^a   Schäfer Korting, Monika ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^d BASF SE   (Germany)

^e HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

Biotransformation human skin; Esterase activity; Fluorescein diacetate; Prednicarbate; Reconstructed human skin

Indexed keywords

ESTERASE; FLUORESCEIN DIACETATE; PREDNICARBATE;

ARTICLE; CELL CULTURE; DRUG ABSORPTION; DRUG TRANSFORMATION; ENZYME ACTIVITY; EPIDERMIS; FIBROBLAST; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; MONOLAYER CULTURE; NORMAL HUMAN;

BIOTRANSFORMATION; CELL LINE; CRYOPRESERVATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDERMIS; ESTERASES; FIBROBLASTS; FLUORESCEINS; HUMANS; KERATINOCYTES; PREDNISOLONE; REPRODUCIBILITY OF RESULTS; SKIN ABSORPTION; TIME FACTORS;

EID: 84878313855     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2012.11.008     Document Type: Article

References (70)

1. H. Kandarova, Evaluation and Validation of Reconstructed Human Skin Models as Alternatives to Animal Tests in Regulatory Toxicology, PhD thesis, Department of Biology, Chemistry and Pharmacy, Freie Universität Berlin, Berlin, 2006, pp. 167.
2. F. Netzlaff, C.M. Lehr, P.W. Wertz, and U.F. Schaefer SkinEthic and EpiDerm: an evaluation of morphology and their suitability for testing phototoxicity, irritancy, corrosivity, and substance transport, the human epidermis models EpiSkin Eur. J. Pharm. Biopharm. 60 2005 167 178
3. H. Kandarova, M. Liebsch, H. Spielmann, E. Genschow, E. Schmidt, D. Traue, R. Guest, A. Whittingham, N. Warren, A.O. Gamer, M. Remmele, T. Kaufmann, E. Wittmer, B. De Wever, and M. Rosdy Assessment of the human epidermis model SkinEthic RHE for in vitro skin corrosion testing of chemicals according to new OECD TG 431 Toxicol. in Vitro 20 2006 547 559
4. M. Katoh, F. Hamajima, T. Ogasawara, and K. Hata Assessment of the human epidermal model LabCyte EPI-MODEL for in vitro skin corrosion testing according to the OECD test guideline 431 J. Toxicol. Sci. 35 2010 411 417
5. OECD, Test Guideline 431: In Vitro Skin Corrosion: Human Skin Model Test, OECD Guidelines for the Testing of Chemicals, Section 4, 2004.
6. C. Eskes, T. Cole, S. Hoffmann, A. Worth, A. Cockshott, I. Gerner, and V. Zuang The ECVAM international validation study on in vitro tests for acute skin irritation: selection of test chemicals Altern. Lab. Anim. 35 2007 603 619
7. OECD, Test Guideline 439: In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method, OECD Guidelines for the Testing of Chemicals, Section 4, 2010.
8. H. Spielmann, S. Hoffmann, M. Liebsch, P. Botham, J.H. Fentem, C. Eskes, R. Roguet, J. Cotovio, T. Cole, A. Worth, J. Heylings, P. Jones, C. Robles, H. Kandarova, A. Gamer, M. Remmele, R. Curren, H. Raabe, A. Cockshott, I. Gerner, and V. Zuang The ECVAM international validation study on in vitro tests for acute skin irritation: report on the validity of the EPISKIN and EpiDerm assays and on the Skin Integrity Function Test Altern. Lab. Anim. 35 2007 559 601
9. I. Gerner, M. Liebsch, and H. Spielmann Assessment of the eye irritating properties of chemicals by applying alternatives to the Draize rabbit eye test: the use of QSARs and in vitro tests for the classification of eye irritation Altern. Lab. Anim. 33 2005 215 237
10. D. Lelievre, P. Justine, F. Christiaens, N. Bonaventure, J. Coutet, L. Marrot, and J. Cotovio The EpiSkin phototoxicity assay (EPA): development of an in vitro tiered strategy using 17 reference chemicals to predict phototoxic potency Toxicol. in Vitro 21 2007 977 995
11. OECD, Test Guideline 432: In vitro 3T3 NRU phototoxicity test, OECD Guidelines for the Testing of Chemicals, Section 4, 2004.
12. F. Netzlaff, M. Kaca, U. Bock, E. Haltner-Ukomadu, P. Meiers, C.M. Lehr, and U.F. Schaefer Permeability of the reconstructed human epidermis model Episkin in comparison to various human skin preparations Eur. J. Pharm. Biopharm. 66 2007 127 134
13. M. Schäfer-Korting, U. Bock, W. Diembeck, H.J. Düsing, A. Gamer, E. Haltner-Ukomadu, C. Hoffmann, M. Kaca, H. Kamp, S. Kersen, M. Kietzmann, H.C. Korting, H.U. Krächter, C.M. Lehr, M. Liebsch, A. Mehling, C. Müller-Goymann, F. Netzlaff, F. Niedorf, M.K. Rübbelke, U. Schaefer, E. Schmidt, S. Schreiber, H. Spielmann, A. Vuia, and M. Weimer The use of reconstructed human epidermis for skin absorption testing: results of the validation study Altern. Lab. Anim. 36 2008 161 187
14. K. Ackermann, S.L. Borgia, H.C. Korting, K.R. Mewes, and M. Schäfer-Korting The Phenion full-thickness skin model for percutaneous absorption testing Skin Pharmacol. Physiol. 23 2010 105 112
15. M. Schäfer-Korting, A. Mahmoud, S. Lombardi Borgia, B. Brüggener, B. Kleuser, S. Schreiber, and W. Mehnert Reconstructed epidermis and full-thickness skin for absorption testing: influence of the vehicles used on steroid permeation Altern. Lab. Anim. 36 2008 441 452
16. S. Gregoire, C. Patouillet, C. Noe, I. Fossa, F. Benech Kieffer, and C. Ribaud Improvement of the experimental setup for skin absorption screening studies with reconstructed skin EPISKIN Skin Pharmacol. Physiol. 21 2008 89 97
17. S. Lombardi Borgia, P. Schlupp, W. Mehnert, and M. Schäfer-Korting In vitro skin absorption and drug release-a comparison of six commercial prednicarbate preparations for topical use Eur. J. Pharm. Biopharm. 68 2008 380 389
18. C. Santos Maia, W. Mehnert, M. Schaller, H.C. Korting, A. Gysler, A. Haberland, and M. Schäfer-Korting Drug targeting by solid lipid nanoparticles for dermal use J. Drug Target 10 2002 489 495
19. S. Gibbs, J.J. van de Sandt, H.F. Merk, D.J. Lockley, R.U. Pendlington, and C.K. Pease Xenobiotic metabolism in human skin and 3D human skin reconstructs: a review Curr. Drug Metab. 8 2007 758 772
20. K. Kubota, J. Ademola, and H.I. Maibach Metabolism of topical drugs within the skin, in particular glucocorticoids Curr. Probl. Dermatol. 21 1993 61 66
21. F. Oesch Importance of knowledge on drug metabolism for the safe use of drugs in humans Drug Metab. Rev. 41 2009 298 300
22. F. Oesch, E. Fabian, B. Oesch-Bartlomowicz, C. Werner, and R. Landsiedel Drug-metabolizing enzymes in the skin of man, rat, and pig Drug Metab. Rev. 39 2007 659 698
23. T. Hu, Z.S. Khambatta, P.J. Hayden, J. Bolmarcich, R.L. Binder, M.K. Robinson, G.J. Carr, J.P. Tiesman, B.B. Jarrold, R. Osborne, T.D. Reichling, S.T. Nemeth, and M.J. Aardema Xenobiotic metabolism gene expression in the EpiDermin vitro 3D human epidermis model compared to human skin Toxicol. in Vitro 24 2010 1450 1463
24. V. Luu-The, C. Ferraris, D. Duche, P. Belanger, J. Leclaire, and F. Labrie Steroid metabolism and profile of steroidogenic gene expression in Episkin: high similarity with human epidermis J. Steroid Biochem. Mol. Biol. 107 2007 30 36
25. C. Götz, R. Pfeiffer, J. Tigges, K. Ruwiedel, U. Hubenthal, H.F. Merk, J. Krutmann, R.J. Edwards, J. Abel, C. Pease, C. Goebel, N. Hewitt, and E. Fritsche Xenobiotic metabolism capacities of human skin in comparison with a 3D-epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: phase II enzymes Exp. Dermatol. 21 2012 364 369
26. C. Götz, R. Pfeiffer, J. Tigges, V. Blatz, C. Jäckh, E.M. Freytag, E. Fabian, R. Landsiedel, H.F. Merk, J. Krutmann, R.J. Edwards, C. Pease, C. Goebel, N. Hewitt, and E. Fritsche Xenobiotic metabolism capacities of human skin in comparison with a 3D epidermis model and keratinocyte-based cell culture as in vitro alternatives for chemical testing: activating enzymes Phase I Exp. Dermatol. 21 2012 358 363
27. V. Luu-The, D. Duche, C. Ferraris, J.R. Meunier, J. Leclaire, and F. Labrie Expression profiles of phases 1 and 2 metabolizing enzymes in human skin and the reconstructed skin models Episkin and full thickness model from Episkin J. Steroid Biochem. Mol. Biol. 116 2009 178 186
28. M.M. Neis, A. Wendel, T. Wiederholt, Y. Marquardt, S. Joussen, J.M. Baron, and H.F. Merk Expression and induction of cytochrome P450 isoenzymes in human skin equivalents Skin Pharmacol. Physiol. 23 2010 29 39
29. H. Bando, S. Mohri, F. Yamashita, Y. Takakura, and M. Hashida Effects of skin metabolism on percutaneous penetration of lipophilic drugs J. Pharm. Sci. 86 1997 759 761
30. K. Kubota, J. Ademola, and H.I. Maibach Simultaneous diffusion and metabolism of betamethasone 17-valerate in the living skin equivalent J. Pharm. Sci. 84 1995 1478 1481
31. J.E. Storm, S.W. Collier, R.F. Stewart, and R.L. Bronaugh Metabolism of xenobiotics during percutaneous penetration: role of absorption rate and cutaneous enzyme activity Fundam. Appl. Toxicol. 15 1990 132 141
32. C.K. Svensson Biotransformation of drugs in human skin Drug Metab. Dispos. 37 2009 247 253
33. A. Gysler, B. Kleuser, W. Sippl, K. Lange, H.C. Korting, H.D. Höltje, and M. Schäfer-Korting Skin penetration and metabolism of topical glucocorticoids in reconstructed epidermis and in excised human skin Pharm. Res. 16 1999 1386 1391
34. K. Lange, B. Kleuser, A. Gysler, M. Bader, C. Maia, C. Scheidereit, H.C. Korting, and M. Schäfer-Korting Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids Skin Pharmacol. Appl. Skin Physiol. 13 2000 93 103
35. M. Schäfer-Korting, B. Kleuser, M. Ahmed, H.D. Höltje, and H.C. Korting Glucocorticoids for human skin: new aspects of the mechanism of action Skin Pharmacol. Physiol. 18 2005 103 114
36. M. Schäfer-Korting, H.C. Korting, M.J. Kerscher, and S. Lenhard Prednicarbate activity and benefit/risk ratio in relation to other topical glucocorticoids Clin. Pharmacol. Ther. 54 1993 448 456
37. J. Wohlrab, G.M. Beck, R.H. Neubert, U. Sischka, and B. Kreft Hydrocortisone aceponate activity and benefit/risk ratio in relation to reference topical glucocorticoids Skin Pharmacol. Physiol. 23 2010 177 182
38. A. Gysler, K. Lange, H.C. Korting, and M. Schäfer-Korting Prednicarbate biotransformation in human foreskin keratinocytes and fibroblasts Pharm. Res. 14 1997 793 797
39. I. Spika, S. Hammer, B. Kleuser, H.C. Korting, and M. Schäfer-Korting Transcriptional activity of potent glucocorticoids: relevance of glucocorticoid receptor isoforms and drug metabolites Skin Pharmacol. Appl. Skin Physiol. 16 2003 143 150
40. A. Haberland, S. Schreiber, C.S. Maia, M.K. Rübbelke, M. Schaller, H.C. Korting, B. Kleuser, I. Schimke, and M. Schäfer-Korting The impact of skin viability on drug metabolism and permeation-BSA toxicity on primary keratinocytes Toxicol. in Vitro 20 2006 347 354
41. G. Weindl, F. Castello, and M. Schäfer-Korting Evaluation of anti-inflammatory and atrophogenic effects of glucocorticoids on reconstructed human skin Altern. Lab. Anim. 39 2011 173 187
42. S. Mitriaikina, and C.C. Müller-Goymann Comparative permeation studies of nondiluted and diluted betamethasone-17-valerate semisolid formulations through isolated human stratum corneum and artificial skin construct Skin Pharmacol. Physiol. 22 2009 142 150
43. P. Schlupp, T. Blaschke, K.D. Kramer, H.D. Höltje, W. Mehnert, and M. Schäfer-Korting Drug release and skin penetration from solid lipid nanoparticles and a base cream: a systematic approach from a comparison of three glucocorticoids Skin Pharmacol. Physiol. 24 2011 199 209
44. 2+ differentially influence extracellular matrix production by human skin in organ culture Am. J. Pathol. 142 1993 1813 1822
45. G. Weindl, J.R. Naglik, S. Kaesler, T. Biedermann, B. Hube, H.C. Korting, and M. Schaller Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling J. Clin. Invest. 117 2007 3664 3672
46. F. Beisson, M. Aoubala, S. Marull, A.M. Moustacas-Gardies, R. Voultoury, R. Verger, and V. Arondel Use of the tape stripping technique for directly quantifying esterase activities in human stratum corneum Anal. Biochem. 290 2001 179 185
47. E. Lindhagen, P. Nygren, and R. Larsson The fluorometric microculture cytotoxicity assay Nat. Protoc. 3 2008 1364 1369
48. I. Brinkmann, C. Müller-Goymann, Prednicarbate permeation through artificial skin construct from different formulations and their dilutions, in: Proceedings of the International Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Nuremberg, 2004.
49. M. Schäfer-Korting, U. Bock, A. Gamer, A. Haberland, E. Haltner-Ukomadu, M. Kaca, H. Kamp, M. Kietzmann, H.C. Korting, H.U. Krächter, C.M. Lehr, M. Liebsch, A. Mehling, F. Netzlaff, F. Niedorf, M.K. Rübbelke, U. Schäfer, E. Schmidt, S. Schreiber, K.R. Schröder, H. Spielmann, and A. Vuia Reconstructed human epidermis for skin absorption testing: results of the German prevalidation study Altern. Lab. Anim. 34 2006 283 294
50. Q.G. Zhu, J.H. Hu, J.Y. Liu, S.W. Lu, Y.X. Liu, and J. Wang Stereoselective characteristics and mechanisms of epidermal carboxylesterase metabolism observed in HaCaT keratinocytes Biol. Pharm. Bull. 30 2007 532 536
51. C. Jewell, J.J. Prusakiewicz, C. Ackermann, N.A. Payne, G. Fate, and F.M. Williams The distribution of esterases in the skin of the minipig Toxicol. Lett. 173 2007 118 123
52. C. Jewell, C. Ackermann, N.A. Payne, G. Fate, R. Voorman, and F.M. Williams Specificity of procaine and ester hydrolysis by human, minipig, and rat skin and liver Drug Metab. Dispos. 35 2007 2015 2022
53. K. Lange, A. Gysler, M. Bader, B. Kleuser, H.C. Korting, and M. Schäfer-Korting Prednicarbate versus conventional topical glucocorticoids: pharmacodynamic characterization in vitro Pharm. Res. 14 1997 1744 1749
54. S.N. Lavergne, B.K. Park, and D.J. Naisbitt The roles of drug metabolism in the pathogenesis of T-cell-mediated drug hypersensitivity Curr. Opin. Allergy Clin. Immunol. 8 2008 299 307
55. I. Andreu, C. Mayorga, and M.A. Miranda Metabolomics in drug intolerance Curr. Drug Metab. 10 2009 947 955
56. A. Valotis, and P. Högger Significant receptor affinities of metabolites and a degradation product of mometasone furoate Respir Res. 5 2004 7
57. C. Schackert, H.C. Korting, and M. Schäfer-Korting Qualitative and quantitative assessment of the benefit-risk ratio of medium potency topical corticosteroids in vitro and in vivo: characterisation of drugs with an increased benefit-risk ratio BioDrugs 13 2000 267 277
58. U. Münster, S. Hammer, U. Blume-Peytavi, and M. Schäfer-Korting Testosterone metabolism in human skin cells in vitro and its interaction with estradiol and dutasteride Skin Pharmacol. Appl. Skin Physiol. 16 2003 356 366
59. S. Schoepe, H. Schacke, A. Bernd, N. Zöllner, and K. Asadullah Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy Skin Pharmacol. Physiol. 23 2010 139 151
60. N.N. Zöller, S. Kippenberger, D. Thaci, K. Mewes, M. Spiegel, A. Sattler, M. Schultz, J. Bereiter-Hahn, R. Kaufmann, and A. Bernd Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model Toxicol. in Vitro 22 2008 747 759
61. L. Semlin, M. Schäfer-Korting, C. Borelli, and H.C. Korting In vitro models for human skin disease Drug Discov. Today 16 2011 132 139
62. M. Van Gele, B. Geusens, L. Brochez, R. Speeckaert, and J. Lambert Three-dimensional skin models as tools for transdermal drug delivery: challenges and limitations Expert Opin. Drug Deliv. 8 2011 705 720
63. K. Abdulmajed, C. McGuigan, and C.M. Heard Topical delivery of retinyl ascorbate co-drug. 5. In vitro degradation studies Skin Pharmacol. Physiol. 19 2006 248 258
64. OECD, Test Guideline 428: Skin Absorption: In Vitro Method, OECD Guidelines for the Testing of Chemicals, Section 4, 2004.
65. M. Ponec, E. Boelsma, S. Gibbs, and M. Mommaas Characterization of reconstructed skin models Skin Pharmacol. Appl. Skin Physiol. 15 Suppl 1 2002 4 17
66. K. Sugibayashi, T. Hayashi, and Y. Morimoto Simultaneous transport and metabolism of ethyl nicotinate in hairless rat skin after its topical application: the effect of enzyme distribution in skin J. Control Release 62 1999 201 208
67. T. Imai, M. Taketani, M. Shii, M. Hosokawa, and K. Chiba Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine Drug Metab. Dispos. 34 2006 1734 1741
68. K.M. Eckl, T. Alef, S. Torres, and H.C. Hennies Full-thickness human skin models for congenital ichthyosis and related keratinization disorders J. Invest. Dermatol. 131 2011 1938 1942
69. V. Oji, K.M. Eckl, K. Aufenvenne, M. Natebus, T. Tarinski, K. Ackermann, N. Seller, D. Metze, G. Nurnberg, R. Folster-Holst, M. Schäfer-Korting, I. Hausser, H. Traupe, and H.C. Hennies Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease Am. J. Hum. Genet 87 2010 274 281
70. S. Küchler, D. Henkes, K.M. Eckl, K. Ackermann, J. Plendl, H.C. Korting, H.C. Hennies, and M. Schäfer-Korting Hallmarks of atopic skin mimicked in vitro by means of a skin disease model based on FLG knock-down Altern. Lab. Anim. 39 2011 471 480